Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported positive results from a Phase 1a study evaluating CRB-913 for chronic obesity management. The news sent the company's shares up more than 14% in pre-market trading.
In the single ascending dose (SAD) and multiple ascending dose (MAD) study, participants treated with CRB-913 achieved a mean 2.9% placebo-adjusted weight loss by day 14. The drug was reported to be safe and well-tolerated across all doses, with no serious treatment-emergent adverse events observed.
A Phase 1b dose-range finding study dubbed CANYON-1 is currently underway and is expected to be completed in summer 2026.
Corbus Pharmaceuticals' stock closed Wednesday at $10.26, up 1.58%.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.